A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multiple-dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Oral VX-708 in Healthy Subjects
Latest Information Update: 17 May 2023
At a glance
- Drugs VX 708 (Primary)
- Indications Acute pain
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
Most Recent Events
- 12 May 2023 Status changed from active, no longer recruiting to completed.
- 19 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 03 May 2022 New trial record